阿帕替尼对老年晚期胃癌患者生活质量的影响及疗效分析

Efficacy of Apatinib and its Effect on Quality of Life of Elderly Patients with Advanced Gastric Cancer

目的探究阿帕替尼对老年晚期胃癌患者的治疗效果及对患者生活质量的影响。方法选取在我院进行治疗的69例老年晚期胃癌患者为研究对象,按照随机数字表法分为实验组(34例)和对照组(35例),对照组患者使用常规抗癌药物进行治疗,实验组患者在对照组基础上联合阿帕替尼进行治疗。两组干预时间均为6周,干预后对两组患者的治疗有效率进行比较,使用QLQ STO-22量表对两组患者干预前、干预第3周及第6周的生活质量进行评价,对两组患者干预过程中的不良反应发生率进行对比。结果实验组患者治疗有效率明显高于对照组(P<0.05)。干预前两组患者STO-22量表评分比较,差异无统计学意义(P>0.05),干预第3周及第6周,实验组患者STO-22评分均明显低于对照组(P<0.05)。实验组干预过程中的不良反应发生率为20.59%(7/34),对照组为28.57%(10/35),差异无统计学意义(P>0.05)。结论阿帕替尼可显著提高老年晚期胃癌患者的治疗效果,改善患者的生活质量,且安全性较高。

Objective To explore the therapeutic effect of apatinib on elderly patients with advanced gastric cancer and its influence on the quality of life of patients.Methods Sixty-nine elderly patients with advanced gastric cancer treated in our hospital were selected as study subjects.They were divided into experiment group(34 cases)and control group(35 cases)according to random number table method.Patients in the control group were treated with conventional anti-cancer drugs.Those in the experiment group were treated with apatinib on the basis of treatment of control group.The intervention time was six weeks.After intervention,the treatment efficacy of the two groups was evaluated and compared.The QLQ STO-22 scale was used to assess the quality of life of the two groups before intervention,at the 3rd and the 6th week of intervention.Finally,the incidence of adverse reactions during the intervention of the two groups of patients was compared.Results The effective rate of treatment in the experiment group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).Before intervention,there was no statistical difference in QLQ STO-22 scores between the two groups(P>0.05).However,the STO-22 scores of the experiment group at the 3rd week and the 6th week of intervention were significantly lower than those of the control group(P<0.05).The incidence of adverse reactions during the intervention in experiment group was 20.59%(7/34),and it was 28.57%(10/35)in control group.There was no significant difference between the two groups(P>0.05).Conclusions Apatinib can significantly enhance the therapeutic efficacy for elderly patients with advanced gastric cancer,and improve the quality of life of patients,with high safety.